138 related articles for article (PubMed ID: 10701363)
1. Enhancement of 5-fluorouracil anabolism by methotrexate and trimetrexate in two rat solid tumor models, Walker 256 carcinosarcoma and Novikoff hepatoma, as evaluated by 19F-magnetic resonance spectroscopy.
Katzir I; Shani J; Wolf W; Chatterjee-Parti S; Berman E
Cancer Invest; 2000; 18(1):20-7. PubMed ID: 10701363
[TBL] [Abstract][Full Text] [Related]
2. In vivo measurements of intratumoral metabolism, modulation, and pharmacokinetics of 5-fluorouracil, using 19F nuclear magnetic resonance spectroscopy.
el-Tahtawy A; Wolf W
Cancer Res; 1991 Nov; 51(21):5806-12. PubMed ID: 1933851
[TBL] [Abstract][Full Text] [Related]
3. Enhanced 5-fluorouracil cytotoxicity and elevated 5-fluoronucleotides in the rat Walker carcinosarcoma following methotrexate pre-treatment: a 19F-MRS study in vivo.
McSheehy PM; Prior MJ; Griffiths JR
Br J Cancer; 1992 Mar; 65(3):369-75. PubMed ID: 1558790
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of fluorouracil uptake in human colorectal and gastric cancers by interferon or by high-dose methotrexate: An in vivo human study using noninvasive (19)F-magnetic resonance spectroscopy.
Presant CA; Wolf W; Waluch V; Wiseman CL; Weitz I; Shani J
J Clin Oncol; 2000 Jan; 18(2):255-61. PubMed ID: 10637237
[TBL] [Abstract][Full Text] [Related]
5. Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracil, in CCRF-CEM cells.
Romanini A; Li WW; Colofiore JR; Bertino JR
J Natl Cancer Inst; 1992 Jul; 84(13):1033-8. PubMed ID: 1376779
[TBL] [Abstract][Full Text] [Related]
6. Biomodulation of 5-fluorouracil with antifolates.
Bertino JR
Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-52-S18-56. PubMed ID: 9420021
[TBL] [Abstract][Full Text] [Related]
7. Locoregional administration of 5-fluoro-2'-deoxyuridine (FdUrd) in Novikoff hepatoma in the rat: effects of dose and infusion time on tumor growth and on FdUrd metabolite levels in tumor tissue as determined by 19F-NMR spectroscopy.
Naser-Hijazi B; Berger MR; Schmähl D; Schlag P; Hull WE
J Cancer Res Clin Oncol; 1991; 117(4):295-304. PubMed ID: 1829730
[TBL] [Abstract][Full Text] [Related]
8. 5-Fluorouracil metabolism and cytotoxicity after pre-treatment with methotrexate or thymidine in human hypopharynx and colon carcinoma xenografts: a 19F-nuclear magnetic resonance spectroscopy study in vivo.
Tausch-Treml R; Baumgart F; Ziessow D; Köpf-Maier P
Cancer Chemother Pharmacol; 1996; 37(3):259-65. PubMed ID: 8529287
[TBL] [Abstract][Full Text] [Related]
9. Direct detection of intratumoral 5-fluorouracil trapping using metabolic 19F MR imaging.
Brix G; Bellemann ME; Gerlach L; Haberkorn U
Magn Reson Imaging; 1999 Jan; 17(1):151-5. PubMed ID: 9888408
[TBL] [Abstract][Full Text] [Related]
10. Metabolites of 5-fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment.
Hull WE; Port RE; Herrmann R; Britsch B; Kunz W
Cancer Res; 1988 Mar; 48(6):1680-8. PubMed ID: 3125967
[TBL] [Abstract][Full Text] [Related]
11. Sequential methotrexate (MTX) and 5-fluorouracil (FU) in human tumor xenografts.
Wayss K; Herrmann R; Mattern J; Volm M
Med Oncol Tumor Pharmacother; 1985; 2(1):27-32. PubMed ID: 4058075
[TBL] [Abstract][Full Text] [Related]
12. Trimetrexate: experience with solid tumors.
Haller DG
Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-71-S18-76. PubMed ID: 9420024
[TBL] [Abstract][Full Text] [Related]
13. Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma.
Conti JA; Kemeny N; Seiter K; Goker E; Tong W; André M; Ragusa K; Bertino JR
J Clin Oncol; 1994 Apr; 12(4):695-700. PubMed ID: 7512128
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil.
Hudes GR; LaCreta F; DeLap RJ; Grillo-Lopez AJ; Catalano R; Comis RL
Cancer Chemother Pharmacol; 1989; 24(2):117-22. PubMed ID: 2525077
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the biodistribution and metabolism of 5-fluorouracil as monitored by 18F PET and 19F MRI: a comparative animal study.
Brix G; Bellemann ME; Haberkorn U; Gerlach L; Lorenz WJ
Nucl Med Biol; 1996 Oct; 23(7):897-906. PubMed ID: 8971857
[TBL] [Abstract][Full Text] [Related]
16. Implications for improved high-dose methotrexate therapeutic effects in cultured human breast cancer and bone marrow cells.
Bowen D; Southerland WM; Johnson DH; Hawkins M; Hughes DE
Cancer Detect Prev; 2000; 24(5):452-8. PubMed ID: 11129987
[TBL] [Abstract][Full Text] [Related]
17. Biochemical modulation of the catabolism and tissue uptake of the anticancer drug 5-fluorouracil by 5-bromovinyluracil: assessment with metabolic (19)F MR imaging.
Brix G; Bellemann ME; Haberkorn U
Magn Reson Med; 1999 Nov; 42(5):936-43. PubMed ID: 10542353
[TBL] [Abstract][Full Text] [Related]
18. [In-vivo 19F-MRS study of 5-fluorouracil (5-FU) metabolism on tumors].
Harada M; Nishitani H; Shirahama T; Koga K; Miura I
Gan To Kagaku Ryoho; 1991 Jan; 18(1):75-80. PubMed ID: 1899014
[TBL] [Abstract][Full Text] [Related]
19. Mapping the biodistribution and catabolism of 5-fluorouracil in tumor-bearing rats by chemical-shift selective 19F MR imaging.
Brix G; Bellemann ME; Haberkorn U; Gerlach L; Bachert P; Lorenz WJ
Magn Reson Med; 1995 Sep; 34(3):302-7. PubMed ID: 7500866
[TBL] [Abstract][Full Text] [Related]
20. Pre-treatment energy status of primary rat tumours as the best predictor of response to 5-fluorouracil chemotherapy: a magnetic resonance spectroscopy study in vivo.
Lemaire LP; McSheehy PM; Griffiths JR
Cancer Chemother Pharmacol; 1998; 42(3):201-9. PubMed ID: 9685055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
